Shanghai Weizhizhuo Biotechnology
Hexaell Biotech is a biopharmaceutical company focused on severe liver disease and cell therapy
About Shanghai Weizhizhuo Biotechnology
Shanghai Weizhizhuo Biotechnology Co., Ltd., operating under the brand Hexaell Biotech, is a biopharmaceutical company established in 2015 with a focus on developing therapies for severe liver diseases. The company is strategically located in Shanghai, with a research and development center in Zhangjiang High-Tech Park and a production base in Jiading Industrial Park. Hexaell's establishment addresses a significant unmet medical need in China, where liver diseases are prevalent and the availability of donor livers for transplantation is critically low.
The company's core technology revolves around a cell differentiation and production platform. Its main product candidate is the HepaCure Bioartificial Liver, a liver support system that functions as a device-drug combination product. This system utilizes a proprietary cell transdifferentiation technology known as hiHeps, which converts human fibroblasts directly into functional hepatocyte-like cells. During treatment, a patient's plasma is processed through a bioreactor containing these hiHeps cells. This process aims to remove toxins from the blood, supply essential liver-specific proteins, reduce inflammation, and stimulate the regeneration of the patient's own liver. This approach offers a new therapeutic option for patients suffering from various forms of liver failure.
Hexaell has made significant progress in its development pipeline. In July 2017, the company established the first domestic production line for the clinical research and development of its human hepatocyte-derived bioartificial liver. A major milestone was achieved in December 2022, when China's National Medical Products Administration (NMPA) cleared the Investigational New Drug (IND) application for the HepaCure Biocolumn, allowing the company to proceed with clinical trials. The firm has successfully attracted venture capital to finance its operations and research. Notably, it completed a Series A funding round of ¥50 million ($7.24 million) in late 2018 and a substantial Series B+ financing of 200 million yuan in February 2025. This capital is being used to advance clinical research, scale up commercial production capabilities, and develop its pipeline of future therapies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Industry
- Health
- Sector
- Biotechnology, Hard Tech
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Apr 2026 | $15M | $155M | Guangdong Technology Financial Group · Fuho Capital · Shenzhen Capital Group · Cuiheng Group | ↗ |
| SERIES BOther financing | Feb 2025 | $31M | $124M | Longpan Investment · SHC Shanghai Biomedical Fund | ↗ |
Growth signals
Latest recorded traffic for Shanghai Weizhizhuo Biotechnology is 100 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shanghai Weizhizhuo Biotechnology in the Huangpu ecosystem
The Shanghai Weizhizhuo Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
SHC Shanghai Biomedical Fund- LILongpan Investment
Guangdong Technology Financial Group- FCFuho Capital
Shenzhen Capital Group- CGCuiheng Group
- ZFZhongshan Financial
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Weizhizhuo Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Weizhizhuo Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






